PD-1/PD-L1-IN-52

• UNSPSC Description:

  PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6%[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-pd-l1-in-52.html

• Smiles:

  OC[C@H](C(OCC)=O)NCC1=CC(Cl)=C(OCC2=C(C)C(C3=CC=CC(OCCCN4N=NC(CN[C@@H](C(OCC)=O)CO)=C4)=C3C)=CC=C2)C=C1OCC5=CC(C#N)=CN=C5

• Molecular Weight:

  870.39

• References & Citations:

  [1]Xia Y, et al. Design, synthesis, and antitumor activity evaluation of 1,2,3-triazole derivatives as potent PD-1/PD-L1 inhibitors. Bioorg Chem. 2024 Sep 7;153:107813.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported